Fig. 2

The Impacts of Somatic Copy Number Alterations in PDAC Cohort. A Significant arm-level focal peaks detected using GISTIC. B Focal-level SCNA events. Focal peaks with significant copy-number gains (red) and losses (blue) (GISTIC2 FDR < 0.05) are shown. The focal peaks are highlighted in approximate positions across the genome. C Venn diagram depicting the process of screening for TFs with cis-effect between CNA and protein. D The heatmap showing the cis-effect of IRF6 among CNA, RNA, protein, and phosphosite (Spearman’s correlation). The P value of correlation is noted on the left. E Kaplan–Meier curves for overall survival based on mRNA abundance of IRF6 (left), and TF activity of IRF6 (right) in Fudan cohort (log-rank test). F Kaplan–Meier curves for overall survival based on mRNA abundance of IRF6 in TCGA-PAAD dataset (log-rank test). G Spearman-rank correlation of the abundance of IRF6 and its target genes (Spearman’s correlation). The significant correlations are colored in dark gray. Cell cycle and cell proliferation-associated proteins are labeled in pink, and prognostic related proteins are labeled with purple circles. H The scatter plot describing the Spearman’s correlation between IRF6 protein expression and GSVA score of cell proliferation. I Kaplan–Meier curves for overall survival based on GSVA scores of cell proliferation (log-rank test). J, K The scatter plot describing the Spearman’s correlation between MCM4 protein expression and MGPS score (J) or tumor size (K). L The systematic diagram summarizing the impact of the cis-effect of GRB7 amplification on increasing tumor size. M The boxplot revealing the comparison of GSVA score of cell proliferation between the younger patients (≤ 60) and the older patients (> 60) (Student’s t test). N The forest plot indicating the hazard ratio of KRAS, TP53, SMAD4, and CDKN2A, in younger patients (left) and older patients (right). O The pathway heatmap indicating the enriched pathways in the four groups (TP53 mut, younger patients; WT, younger patients; TP53 mut, older patients; WT, older patients). Each column represents a type of sample. The color of each cell shows -log₁₀ transformed P value. P Venn diagram depicting the process of screening for highly expressed kinase in younger patients with TP53 mutations. Q The boxplot revealing the comparison of CDK4 protein expression between TP53 mutations and WT both in the younger patients (≤ 60) and the older patients (> 60) (Wilcoxon test). R Kaplan–Meier curves for overall survival based on CDK4 abundance in the younger patients (left) or the older patients (right) (log-rank test). S The heatmap showing cell cycle-associated phosphosites which are positively correlated with CDK4. T The systematic diagram summarizing the impact of TP53 mutations on promoting cell cycle. ****p < 1.0E−4, ***p < 1.0E−3, **p < 1.0E−2, *p < 0.05, ns > 0.05